SCHEMBL1328010

SCHEMBL1328010

CCc1cccc(CC)c1-c1cc(C)c(CN2CC(C)CC(C)C2)c(C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 10/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CD274 Q9NZQ7 3/20 0.35
PDCD1 Q15116 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GAA P10253 1/20 0.35
PDCD1LG2 Q9BQ51 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328774 0.88 CYP2A13 (0.46) C5AR1MEN1KMT2AL3MBTL1GAA
SCHEMBL1330231 0.85 C5AR1 (0.39) C5AR1MEN1KMT2ACD274PDCD1
SCHEMBL1328096 0.85 C5AR1 (0.39) C5AR1MEN1KMT2ACD274PDCD1
SCHEMBL1328483 0.84 C5AR1 (0.41) C5AR1GAAALOX15HSD17B10KDM4E
SCHEMBL2137925 0.83 C5AR1 (0.43) C5AR1MEN1KMT2ACD274L3MBTL1
SCHEMBL2141586 0.83 C5AR1 (0.43) C5AR1MEN1KMT2ACD274L3MBTL1
SCHEMBL1328958 0.81 CYP2A13 (0.47) C5AR1MEN1KMT2AGAAHSD17B10
SCHEMBL1329564 0.81 C5AR1 (0.42) C5AR1GAAKDM4EALDH1A1POLB
SCHEMBL2141112 0.80 C5AR1 (0.37) C5AR1CD274PDCD1LG2ALDH1A1
SCHEMBL1329264 0.80 C5AR1 (0.36) C5AR1MEN1KMT2ACD274PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 C5AR1 2/4885MEN1 3563/4885KMT2A 3960/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 C5AR1 2/4885MEN1 3563/4885KMT2A 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.